Patents Assigned to EnGen Bio, Inc.
  • Influenza vaccine and therapy
    Patent number: 10080792
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 25, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
  • Influenza vaccine and therapy
    Patent number: 9999662
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 21, 2014
    Date of Patent: June 19, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark R. Alfenito, Mark Baer, Doris Bucher